Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs

In this new era of highly effective oral antiviral drugs for chronic hepatitis C virus (HCV), indications for antiviral treatment may be extendable. This study undertaken to identify suitable candidates for peg-interferon plus ribavirin (PEG-IFN/RBV) treatment by evaluating hepatocellular carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Seung Ho, Jin, Young-Joo, Shin, Jun Young, Lee, Jin-Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228644/
https://www.ncbi.nlm.nih.gov/pubmed/28072684
http://dx.doi.org/10.1097/MD.0000000000005321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228644/
https://www.ncbi.nlm.nih.gov/pubmed/28072684
http://dx.doi.org/10.1097/MD.0000000000005321

Ejemplares similares